Tycel J. Phillips, MD, on Intravascular DLBCL: Study of Patient Features and Outcomes
2017 ASH Annual Meeting
Tycel J. Phillips, MD, of the University of Michigan Medical School, discusses the findings of the largest retrospective study to date of patients with intravascular diffuse large B-cell lymphoma, a disease with a poor outcome, partly due to the difficulty in diagnosing it early (Abstract 377).
Gilles A. Salles, MD, PhD, of the Université de Lyon, discusses study findings on rituximab maintenance after induction immunochemotherapy and the significant long-term progression-free survival benefit over observation (Abstract 486).
Andrew D. Zelenetz, MD, PhD, of Memorial Sloan Kettering Cancer Center, and Sattva S. Neelapu, MD, of The University of Texas MD Anderson Cancer Center, discuss long-term study findings on axicabtagene ciloleucel in patients with refractory aggressive non-Hodgkin lymphoma (Abstract 578).
Tanaya Shree, MD, PhD, of Stanford University Medical Center, discusses findings from a large population-based study suggesting lasting effects of lymphoma and its treatments: an increased incidence of autoimmune and infectious diseases (Abstract 198).
Joseph M. Connors, MD, of the British Columbia Cancer Agency, discusses study findings on a new front-line option: brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with previously untreated stage III or IV Hodgkin lymphoma (Abstract 6).
Maria-Victoria Mateos, MD, PhD, of the University Hospital of Salamanca, discusses phase III study findings on daratumumab plus bortezomib, melphalan, and prednisone vs bortezomib, melphalan, and prednisone in patients ineligible for transplant who have been newly diagnosed with multiple myeloma (Abstract LBA-4).